I-Corps: Dentifrices With Targeted Drug Release

I-Corps：具有靶向药物释放的洁齿剂

• 批准号: 2342430
• 负责人: Grigoriy Sereda
• 金额: $ 5万
• 依托单位: University of South Dakota Main Campus
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2342430&HistoricalAwards=false
• 关键词: Corps; Dentifrices; Targeted; Drug; Release

The broader impact/commercial potential of this I-Corps project is the development a drug delivery platform to provide medications to areas of interest within the mouth. Currently, treatment options for dentists and their patients are limited. The proposed technology is designed to deliver drugs to both teeth and inflamed gum tissue to treat conditions such as infection, pain, and hypersensitivity. This may allow dual use of tooth desensitizing particles, targeted delivery of medications to the areas in need that may reduce the patient's exposure to the medications, and side effects, and may expand treatment options to take-home dentifrices. In addition, the proposed technology may deliver particles that instantly degrade to non-toxic compounds in the acidic environment of the stomach, which eliminates the issue of clearance from the body and may allow the use of microparticles that are safer than more commonly used. The proposed drug delivery platform may improve treatment options for dentists as well as patient outcomes. This I-Corps project is based on the development of an oral drug delivery platform targeted to treat conditions such as infection, pain, and hypersensitivity. The proposed platform is composed of microparticles of hydroxyapatite, calcium carbonate, or calcium citrate that are loaded with a drug (or drug cocktail), and treated with a coating or other surface modifier. Typical drug candidates include eugenol, fluoride, doxycycline, chlorhexidine, and/or prednisolone. The microparticles are designed to occlude dentinal tubules and/or attach to the gum tissue and release the cargo drug to the oral cavity and to the pulp of the tooth when triggered by a site-specific biochemical stimulus. Depending on how the chemistry is tuned, factors such as adhesion, release rates, and power of hydrogen (pH) sensitivity may be optimized to achieve desired performance. The microparticles can be administered as an active ingredient of a dentifrice, such as a coating on dental floss or a dental device. Research results demonstrate casein-coated microspheres of calcium carbonate loaded with eugenol and fluoride are triggered to release under acidic conditions characteristic of the presence of cariogenic bacteria1 or matrix metalloproteinase-7 (MMP-7) enzyme produced by inflamed tissues. This proposed technology may provide a better understanding of the fundamental aspects of the interaction between small molecules, microscale materials, and biological tissues.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个I-Corps项目更广泛的影响/商业潜力是开发一个药物输送平台，为口腔内感兴趣的区域提供药物。 目前，牙医及其患者的治疗选择有限。这项技术旨在将药物输送到牙齿和发炎的牙龈组织，以治疗感染、疼痛和过敏等疾病。 这可以允许牙齿脱敏颗粒的双重使用，将药物靶向递送到需要的区域，这可以减少患者对药物的暴露和副作用，并且可以将治疗选择扩展到带回家的药物。 此外，所提出的技术可以递送在胃的酸性环境中立即降解为无毒化合物的颗粒，这消除了从身体清除的问题，并且可以允许使用比更常用的更安全的微粒。 所提出的药物输送平台可以改善牙医的治疗选择以及患者的结果。 这个I-Corps项目是基于开发一种口服药物递送平台，旨在治疗感染、疼痛和超敏反应等疾病。所提出的平台由羟基磷灰石、碳酸钙或柠檬酸钙的微粒组成，所述微粒装载有药物（或药物混合物），并且用涂层或其他表面改性剂处理。典型的候选药物包括丁香酚、氟化物、多西环素、氯己定和/或泼尼松龙。所述微粒被设计成当由位点特异性生化刺激触发时，阻塞牙本质小管和/或附着到牙龈组织并将货物药物释放到口腔和牙髓。取决于如何调整化学性质，可以优化诸如粘附性、释放速率和氢的功率（pH）敏感性的因素以实现期望的性能。所述微粒可以作为牙膏的活性成分施用，例如牙线或牙科装置上的涂层。研究结果表明，负载丁香酚和氟化物的碳酸钙的酪蛋白涂层微球在存在致龋细菌1或由发炎组织产生的基质金属蛋白酶-7（MMP-7）酶的酸性条件下被触发释放。 这项提议的技术可能会提供一个更好的理解之间的相互作用的小分子，微尺度材料和生物tissues.This奖项反映了NSF的法定使命的基本方面，并已被认为是值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持。